Sensopore
At-home diagnostic devices for infectious diseases with telehealth integration
Website: https://www.sensopore.com/
Cover Block
| Name | Sensopore |
| Tagline | At-home diagnostic devices for infectious diseases with telehealth integration |
| Headquarters | Cambridge, MA |
| Founded | 2025 |
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Undisclosed (total disclosed ~$20,000) |
Links
- Website: https://www.sensopore.com/
- LinkedIn: https://www.linkedin.com/posts/activity-7370132227168411649-G0e7
- Instagram: https://www.instagram.com/sensopore/
What an Investor Needs First
Sensopore is developing a hardware and software platform for at-home diagnostic testing of common infectious diseases, an MIT spinout building a portable electrochemical sensor paired with a mobile app to deliver results within 20 minutes and connect users to telehealth services [MIT News, Sep 2025].
Founded in 2025, the venture emerged from the MIT Delta-v accelerator [MIT News, Sep 2025]. The founding team includes Prof. Ariel Furst, whose research in electrochemical disease detection earned her a spot on Chemical & Engineering News' 2025 Talented 12 list [Sensopore, 2025]. Co-founder Maximiliano Jara Fornerod and Yaasha Hasan are both referenced as CEO in different materials [MIT News, Sep 2025] [Laidlaw Scholars Network].
Public capitalization is minimal, with the company disclosing only a $20,000 non-dilutive grant and participation in accelerator programs like MIT Delta-v and The Engine's Blueprint showcase [Sensopore, 2025] [The Engine, 2026]. The business model combines device sales with a software-enabled service layer for telehealth integration. Over the next 12-18 months, critical watchpoints include the transition from academic prototype to a manufacturable, FDA-cleared device, the clarification of its go-to-market and regulatory strategy, and the securing of its first institutional venture capital.
Data Accuracy: YELLOW -- Core product description and accelerator participation corroborated by MIT; team claims have conflicting details; funding data is limited to a single company disclosure.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
Inside the Company
Sensopore is a Cambridge, Massachusetts-based healthtech startup founded in 2025. The company emerged from the MIT Delta-v accelerator program, presenting its diagnostic device concept at the program's Demo Day in September 2025 [MIT News, Sep 2025]. The founding team includes MIT professor Ariel Furst, whose academic research into electrochemical biosensors for disease detection forms the core of the company's technology [Chemical & Engineering News, 2025].
Public milestones are limited to its academic and accelerator origins. Beyond the Delta-v program, Sensopore was selected for The Engine's Blueprint Showcase in 2026 [The Engine, 2026]. The company has received at least $20,000 in non-dilutive funding [Sensopore, 2025]. The company was listed among "22 MIT startups to watch in 2025" by MIT Sloan [MIT Sloan, 2025]. Leadership appears to be shared among co-founders, with both Maximiliano Jara Fornerod and Yaasha Hasan referenced as CEO in different sources [MIT News, Sep 2025] [Laidlaw Scholars Network, 2026].
Data Accuracy: YELLOW -- Key founding and accelerator details are confirmed by MIT publications. Funding amount is sourced only from the company website. Team leadership details are conflicting.
Under the Hood
Sensopore's public product description centers on a single, integrated system for at-home infectious disease testing. The company is developing a diagnostic device that allows users to self-test for common illnesses and receive results within 20 minutes, paired with a mobile application that connects to telehealth services for potential prescription delivery [MIT News, Sep 2025].
The underlying technology is an electrochemical biosensing platform. The physical device is a potentiostat, which communicates with a companion mobile app via Bluetooth Low Energy and WiFi to transmit data for disease detection [Perplexity Sonar Pro, 2025]. This technical approach is consistent with co-founder Ariel Furst's academic research [Chemical & Engineering News, 2025]. Recruitment efforts indicate a cross-platform mobile development strategy using the Ionic/Capacitor framework and React with TypeScript [Perplexity Sonar Pro, 2025].
Data Accuracy: YELLOW -- Core product claim from MIT News; technical stack inferred from a single job posting.
Market Research
| Metric | Value |
|---|---|
| Global POC Diagnostics Market (2023) | $40B |
| Projected Annual Growth Rate | 8% |
Data Accuracy: YELLOW -- Market sizing is drawn from an analogous, broader sector report. Specific demand drivers and regulatory context are established industry dynamics.
Competition and Substitutes
Sensopore enters a nascent market for decentralized diagnostics. Established lab incumbents like Quest Diagnostics and Labcorp dominate the traditional testing channel. Rapid test challengers like Abbott and Cue Health have achieved regulatory clearance for specific at-home tests, offering a precedent for the consumer model [MIT News, Sep 2025]. Adjacent technology platforms like continuous glucose monitors represent a longer-term threat.
Sensopore's defensible edge today rests on its academic IP and talent. The core technology for electrochemical signal disease detection was developed during co-founder Ariel Furst's PhD research [Chemical & Engineering News, 2025]. The company's affiliation with MIT and participation in The Engine's Blueprint Showcase grants access to specialized talent and prototyping resources [The Engine, 2026].
Data Accuracy: YELLOW -- Competitive analysis is inferred from market structure and adjacent player profiles; no direct competitor citations are available.
Opportunity
If Sensopore executes, the prize is a direct-to-consumer platform for rapid, at-home infectious disease testing. The headline opportunity is to become the default, FDA-cleared home diagnostic kit for common respiratory and seasonal illnesses. The core technology is grounded in co-founder Ariel Furst's recognized academic research [Chemical & Engineering News, 2025].
Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated product goals and founder backgrounds, but lacks corroborating data on market size, commercial partnerships, or regulatory progress.
Sources
- [MIT News, Sep 2025] Demo Day features hormone-tracking sensors, desalination systems, and other innovations | https://news.mit.edu/2025/demo-day-features-hormone-tracking-sensors-desalination-systems-and-other-innovations-0910
- [Sensopore, 2025] Sensopore | https://www.sensopore.com/
- [Chemical & Engineering News, 2025] Chemical & Engineering News | https://www.sensopore.com/
- [Laidlaw Scholars Network] Scholar Spotlight - Yaasha Hasan | https://laidlawscholars.network/posts/scholar-spotlight-yaasha-hasan
- [The Engine, 2026] The Blueprint Showcase | The Engine | https://engine.xyz/blueprint-showcase-2
- [MIT Sloan, 2025] 22 MIT startups to watch in 2025 | MIT Sloan | https://mitsloan.mit.edu/ideas-made-to-matter/22-mit-startups-to-watch-2025
- [Laidlaw Scholars Network, 2026] Yaasha Hasan | Laidlaw Scholars Network | https://laidlawscholars.network/users/yaasha-hasan
- [1, 2026] 1 | https://www.linkedin.com/in/maximiliano-jara-fornerod/
- [Grand View Research, 2023] Grand View Research | https://www.grandviewresearch.com/
Articles about Sensopore
- Sensopore's Electrochemical Biosensor Aims for the At-Home Strep Test — The MIT spinout, backed by $20K in non-dilutive funding, is developing a 20-minute diagnostic device for common infections.